Drugs / BI 691751
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02148107 | May → Jul 2014 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02057835 | Mar → May 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02044393 | Jan → May 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01843972 | Apr → Nov 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02175238 Comparator | Jul → Oct 2014 | — | Boehringer Ingelheim | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 691751 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02044393 ↗ |
| Action | Inhibit | “this LTA4H-inhibitor” NCT02148107 ↗ |
| Route | Oral | “single dose given as oral solution” NCT01843972 ↗ |
| Target | LTA4H | “this LTA4H-inhibitor” NCT02148107 ↗ |